If the primary non-inferiority objective was confirmed, the non-inferiority/superiority of HPV-16/18(2D) compared to HPV-6/11/16/18(3D) at M7 was evaluated sequentially as a secondary objective based on the criteria defined above. for anti-HPV-16 and 3.22 [2.82C3.68] for anti-HPV-18; p = 0.0001 for all those comparisons. Non-inferiority/superiority was also exhibited at M12. Among initially seronegative girls in the ATP-I, neutralizing antibody titers were at least 1.8-fold higher for HPV-16/18(2D) vs. HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D) at M7 and M12. Frequencies of HPV-16/18-specific T-cells and B-cells were in comparable ranges between groups. Reactogenicity and safety were in line with the known profile of each vaccine. In conclusion, superior HPV-16/18 antibody responses were elicited by 2 doses of the HPV-16/18 AS04-adjuvanted vaccine compared with 2 or 3 3 AMD3100 (Plerixafor) doses of the HPV-6/11/16/18 vaccine in girls (9C14?years). Keywords: administration schedule, female adolescents, immunogenicity, human papillomavirus (HPV) vaccines, safety Abbreviations 2D2-dose3D3-doseAAHSaluminum hydroxyphosphate sulfateANOVAanalysis of varianceAS04Adjuvant System made up of 50?g 3-Rix4446 cell substrate using a baculovirus expression vector system and formulated with AS04, which contains aluminum hydroxide plus an additional immunostimulant, the toll-like receptor 4 agonist monophosphoryl lipid A.38 AS04 has been shown to enhance humoral and cell-mediated immune responses39 by triggering a local and transient cytokine response, leading to increased activation of antigen-presenting cells and an improved presentation of antigen to CD4+ T-cells.38 However, the incidence of transient local solicited symptoms, such as pain, is also increased in vaccines formulated with AS04 compared with aluminum salt alone.37 VLPs for the HPV-6/11/16/18 vaccine are produced in the yeast and formulated with amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant, which has an increased capacity to bind to L1 VLPs compared with aluminum salts.40 Mice immunized with HPV-16 L1 VLPs adsorbed onto AAHS had significantly higher antibody titers than mice immunized with AMD3100 (Plerixafor) VLPs adsorbed to aluminum hydroxide and the AAHS-formulated vaccine induced a substantial L1-specific interferon (IFN) secreting AMD3100 (Plerixafor) T-cell response.40 However, there has not been any direct comparison between AS04 and AAHS adjuvants using identical HPV antigens. A strength of the present study is usually that assessments were performed according to the same schedule and using the same methodology in all groups, allowing a valid head-to-head comparison of immunogenicity and reactogenicity for the 2 2 vaccines. The study AMD3100 (Plerixafor) was also conducted in the age group of young girls that is targeted by most immunization programs. We endeavored to minimize factors which might have introduced bias against either vaccine. The study was conducted in an observer-blind manner to enable the vaccines to be administered according to their recommended schedules. The 2D regimens of each vaccine were administered at months 0 and 6 and the 3D regimen of the HPV-6/11/16/18 vaccine was administered at months 0, 2 and 6, with a placebo administered at month 2 for girls in the 2D groups to maintain blinding. The administration of aluminum hydroxide alone at month 2 would not be expected to affect HPV-specific immune responses. It Rabbit polyclonal to Neuropilin 1 is possible that stimulation of memory B-cells with the L1 VLP constructs from the HPV-16/18 vaccine in the B-cell enzyme-linked immunosorbent spot (ELISPOT) assay might have introduced bias against the HPV-6/11/16/18 vaccine. However, results were not expected to be significantly affected as the HPV-16 and ?18 L1 patented sequences for the 2 2 vaccines are 99.6% and 99.4% identical, respectively, by protein level comparison, with the main differences between the constructs being 33 and 35 amino acid C-terminal truncations of the L1 sequences used in the HPV-16/18 vaccine. Although the ELISA also used the VLPs present in the HPV-16/18 vaccine as the coating antigen for the assay, there did not appear to be a notable bias in favor of the HPV-16/18 vaccine since the magnitude of differences in GMT ratios between groups were comparable when neutralizing antibody titers were measured by PBNA (which used pseudovirions with structures that were as close as possible to those of natural HPV-16 and ?18 virus particles41). Good correlation has been previously exhibited between results from the ELISA measuring total anti-HPV-16/18 IgG independently of their neutralising activity and PBNA detecting neutralizing antibodies.41 Good correlation has also been shown between ELISA, PBNA and the competitive Luminex immunoassay (measuring only a subset of neutralizing antibodies),42 which is primarily used to evaluate the immunogenicity of the HPV-6/11/16/18 vaccine in clinical trials, providing further reassurance that the likelihood of assay bias is minimal. The assay used to evaluate antigen-specific CD4+ T-cell responses was also unlikely to favor either vaccine, since the HPV-16 and ?18 peptide pools used for in vitro stimulation covered the entire L1 VLP sequences of each vaccine. In summary,. AMD3100 (Plerixafor)